Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
455 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Bone Marrow Transplant Rejection - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H1 2017, provides an overview of the Bone Marrow Transplant Rejection (Immunology) pipeline landscape. Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain and shortness of breath. Treatment includes immunosuppressive drugs. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Marrow Transplant Rejection - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Bone Marrow Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 26, 16, 1, 35, 6 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 13 and 3 molecules, respectively. Bone Marrow Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection (Immunology). - The pipeline guide reviews pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Bone Marrow Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Bone Marrow Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection (Immunology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Bone Marrow Transplant Rejection (Immunology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Bone Marrow Transplant Rejection - Overview 11 Bone Marrow Transplant Rejection - Therapeutics Development 12 Pipeline Overview 12 Pipeline by Companies 13 Pipeline by Universities/Institutes 19 Products under Development by Companies 22 Products under Development by Universities/Institutes 28 Bone Marrow Transplant Rejection - Therapeutics Assessment 30 Assessment by Target 30 Assessment by Mechanism of Action 35 Assessment by Route of Administration 40 Assessment by Molecule Type 42 Bone Marrow Transplant Rejection - Companies Involved in Therapeutics Development 44 AbbVie Inc 44 AbGenomics International Inc 44 Actelion Ltd 45 Alexion Pharmaceuticals Inc 45 Allergan Plc 46 Amunix Operating Inc 46 AnaptysBio Inc 47 apceth Biopharma GmbH 47 Aptevo Therapeutics Inc 48 arGEN-X BV 48 Athersys Inc 49 Bellicum Pharmaceuticals Inc 49 Bio-Cancer Treatment International Ltd 50 Biogen Inc 50 Bristol-Myers Squibb Company 51 Cantex Pharmaceuticals Inc 51 Capricor Therapeutics Inc 52 Cell Source Inc 52 Cell2B Advanced Therapeutics SA 53 CellECT Bio Inc 53 Cleveland BioLabs Inc 54 Compugen Ltd 54 Cynata Therapeutics Limited 55 Cytodyn Inc 55 Dompe Farmaceutici SpA 56 Dr. Falk Pharma GmbH 56 Escape Therapeutics Inc 57 F. Hoffmann-La Roche Ltd 57 Fate Therapeutics Inc 58 Generon (Shanghai) Corp Ltd 58 Gilead Sciences Inc 59 GlaxoSmithKline Plc 59 Immunomedics Inc 60 Incyte Corp 60 Jazz Pharmaceuticals Plc 61 Kadmon Corp LLC 61 Kamada Ltd 62 Kiadis Pharma NV 62 Kymab Ltd 63 Kyorin Pharmaceutical Co Ltd 63 MacroGenics Inc 64 Mallinckrodt Plc 64 Medsenic 65 Mesoblast Ltd 65 Millennium Pharmaceuticals Inc 66 Nektar Therapeutics 66 Neovii Pharmaceuticals AG 67 Nohla Therapeutics Inc 67 Novartis AG 68 OncoImmune Inc 68 OSE Immunotherapeutics 69 Pfizer Inc 69 Pharmicell Co Ltd 70 Pluristem Therapeutics Inc 70 REGiMMUNE Corp 71 Sanofi 71 Sarepta Therapeutics Inc 72 Seattle Genetics Inc 72 Seres Therapeutics Inc 73 Sigmoid Pharma Ltd 73 Synedgen Inc 74 Taiga Biotechnologies Inc 74 Takeda Pharmaceutical Company Ltd 75 Targazyme Inc 75 United BioPharma Inc 76 Vault Pharma Inc 76 VBI Vaccines Inc 77 Xenikos BV 77 XL-protein GmbH 78 ZIOPHARM Oncology Inc 78 Bone Marrow Transplant Rejection - Drug Profiles 79 abatacept - Drug Profile 79 AbGn-168H - Drug Profile 87 AGS-499 - Drug Profile 89 aldesleukin - Drug Profile 90 Alecmestencel-L - Drug Profile 92 alpha-1 proteinase inhibitor (human) - Drug Profile 93 ALXN-1007 - Drug Profile 99 AMX-342 - Drug Profile 101 anti-thymocyte globulin (rabbit) - Drug Profile 102 Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile 104 ARGX-115 - Drug Profile 105 arsenic trioxide - Drug Profile 106 ATIR-101 - Drug Profile 107 BCT-200 - Drug Profile 112 begelomab - Drug Profile 113 Biologic to Activate IL-2 for Graft Versus Host Disease - Drug Profile 114 Biologics for Graft Versus Host Disease - Drug Profile 115 bortezomib - Drug Profile 116 brentuximab vedotin - Drug Profile 124 budesonide - Drug Profile 151 C-87 - Drug Profile 155 cannabidiol - Drug Profile 156 CAP-2003 - Drug Profile 159 CBLB-612 - Drug Profile 161 CD-24Fc - Drug Profile 163 Cell Therapy for Graft Versus Host Disease - Drug Profile 165 Cell Therapy for Graft-Versus Host Disease - Drug Profile 166 Cellgram for Graft Versus Host Disease - Drug Profile 167 Cellular Immunotherapy for Acute Graft Versus Host Disease - Drug Profile 168 Cellular Immunotherapy for Autoimmune Diseases and Transplantation - Drug Profile 169 Cellular Immunotherapy for Bone Marrow Transplantation - Drug Profile 171 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 172 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 173 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 174 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 175 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 176 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 177 Cellular Immunotherapy for Graft Versus Host Disease and Multiple Myeloma - Drug Profile 178 cenicriviroc mesylate - Drug Profile 179 CGEN-15001 - Drug Profile 187 CRCBT-080004 - Drug Profile 190 cyclosporine CR + cyclosporine IR - Drug Profile 191 CYP-001 - Drug Profile 192 defibrotide sodium - Drug Profile 194 dociparstat sodium - Drug Profile 203 Echinomycin - Drug Profile 205 entospletinib - Drug Profile 206 ENTXA-2 - Drug Profile 208 ES-210 - Drug Profile 209 F-652 - Drug Profile 210 FR-104 - Drug Profile 212 Ha-7 - Drug Profile 215 HE-33 - Drug Profile 216 ibrutinib - Drug Profile 217 ImmuneSafe - Drug Profile 246 ImmuStem - Drug Profile 247 INX-021 - Drug Profile 248 IT-603 - Drug Profile 250 IT-901 - Drug Profile 251 itacitinib adipate - Drug Profile 253 ixazomib citrate - Drug Profile 256 KD-025 - Drug Profile 266 KRP-203 - Drug Profile 271 KY-1005 - Drug Profile 273 MAX-16H5 - Drug Profile 274 MesoStem - Drug Profile 275 methoxsalen - Drug Profile 276 MGD-010 - Drug Profile 278 milatuzumab - Drug Profile 281 Monoclonal Antibody for Graft Versus Host Disease and Inflammation - Drug Profile 284 Monoclonal Antibody to Activate BTLA for GVHD - Drug Profile 285 Monoclonal Antibody to Inhibit T-Bet for Immunology and Oncology - Drug Profile 286 MPC-CBE - Drug Profile 287 natalizumab - Drug Profile 289 nilotinib - Drug Profile 294 NKTR-358 - Drug Profile 301 obinutuzumab - Drug Profile 302 OCU-300 - Drug Profile 310 Oligonucleotide to Inhibit NFAT1 for GVHD - Drug Profile 311 panobinostat - Drug Profile 312 PF-05285401 - Drug Profile 320 PLXR-18 - Drug Profile 332 ponesimod - Drug Profile 339 Preimplantation Factor - Drug Profile 342 PRO-140 - Drug Profile 344 ProTmune - Drug Profile 353 PTX-15 - Drug Profile 355 Recombinant Protein for Graft Versus Host Disease and Autoimmune Disorders - Drug Profile 356 Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis - Drug Profile 357 Recombinant Protein to Antagonize ILT3 for Graft Versus Host Disease - Drug Profile 358 remestemcel-L - Drug Profile 359 reparixin - Drug Profile 365 RGI-2001 - Drug Profile 368 rimiducid + rivogenlecleucel - Drug Profile 371 rituximab biobetter - Drug Profile 376 RO-2959 - Drug Profile 377 rovalpituzumab tesirine - Drug Profile 378 ruxolitinib phosphate - Drug Profile 380 S-Graft - Drug Profile 395 SER-155 - Drug Profile 396 sirolimus - Drug Profile 397 Small Molecule for Autoimmune Disorders, Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis - Drug Profile 399 Small Molecule to Agonize AhR for Type 1 Diabetes and Graft Versus Host Disease - Drug Profile 400 Small Molecules to Inhibit Perforin for Bone Marrow Transplantation - Drug Profile 401 Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile 402 Small Molecules to Selectively Inhibit ROCK2 for Autoimmune Disorders - Drug Profile 403 sonidegib phosphate - Drug Profile 404 Stem Cell Therapy for Genito Urinary System And Sex Hormone Diseases, Immunology, Metabolic Disorders, Oncology and Respiratory Disease - Drug Profile 409 SYGN-305 - Drug Profile 410 Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease - Drug Profile 411 T-Guard - Drug Profile 412 TBX-1400 - Drug Profile 414 TM-5509 - Drug Profile 415 TZ-101 - Drug Profile 416 vedolizumab - Drug Profile 419 VPI-101 - Drug Profile 426 XL-085 - Drug Profile 427 ZL-1101 - Drug Profile 428 Bone Marrow Transplant Rejection - Dormant Projects 429 Bone Marrow Transplant Rejection - Discontinued Products 433 Bone Marrow Transplant Rejection - Product Development Milestones 434 Featured News & Press Releases 434 Appendix 446 Methodology 446 Coverage 446 Secondary Research 446 Primary Research 446 Expert Panel Validation 446 Contact Us 446 Disclaimer 447
List of Tables
Number of Products under Development for Bone Marrow Transplant Rejection, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 Products under Development by Universities/Institutes, H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Bone Marrow Transplant Rejection - Pipeline by AbbVie Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by AbGenomics International Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Actelion Ltd, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Alexion Pharmaceuticals Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Allergan Plc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Amunix Operating Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by AnaptysBio Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by apceth Biopharma GmbH, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Aptevo Therapeutics Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by arGEN-X BV, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Athersys Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Bio-Cancer Treatment International Ltd, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Biogen Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Bristol-Myers Squibb Company, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Cantex Pharmaceuticals Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Capricor Therapeutics Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Cell Source Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Cell2B Advanced Therapeutics SA, H1 2017 Bone Marrow Transplant Rejection - Pipeline by CellECT Bio Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Cleveland BioLabs Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Compugen Ltd, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Cynata Therapeutics Limited, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Cytodyn Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Dompe Farmaceutici SpA, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Dr. Falk Pharma GmbH, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Escape Therapeutics Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Fate Therapeutics Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Generon (Shanghai) Corp Ltd, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Gilead Sciences Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by GlaxoSmithKline Plc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Immunomedics Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Incyte Corp, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Jazz Pharmaceuticals Plc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Kadmon Corp LLC, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Kamada Ltd, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Kiadis Pharma NV, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Kymab Ltd, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017 Bone Marrow Transplant Rejection - Pipeline by MacroGenics Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Mallinckrodt Plc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Medsenic, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Mesoblast Ltd, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Nektar Therapeutics, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Neovii Pharmaceuticals AG, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Nohla Therapeutics Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Novartis AG, H1 2017 Bone Marrow Transplant Rejection - Pipeline by OncoImmune Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by OSE Immunotherapeutics, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Pfizer Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Pharmicell Co Ltd, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Pluristem Therapeutics Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by REGiMMUNE Corp, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Sanofi, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Sarepta Therapeutics Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Seattle Genetics Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Seres Therapeutics Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Sigmoid Pharma Ltd, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Synedgen Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Taiga Biotechnologies Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Targazyme Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by United BioPharma Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Vault Pharma Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by VBI Vaccines Inc, H1 2017 Bone Marrow Transplant Rejection - Pipeline by Xenikos BV, H1 2017 Bone Marrow Transplant Rejection - Pipeline by XL-protein GmbH, H1 2017 Bone Marrow Transplant Rejection - Pipeline by ZIOPHARM Oncology Inc, H1 2017 Bone Marrow Transplant Rejection - Dormant Projects, H1 2017 Bone Marrow Transplant Rejection - Dormant Projects, H1 2017 (Contd..1), H1 2017 Bone Marrow Transplant Rejection - Dormant Projects, H1 2017 (Contd..2), H1 2017 Bone Marrow Transplant Rejection - Dormant Projects, H1 2017 (Contd..3), H1 2017 Bone Marrow Transplant Rejection - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
